<DOC>
	<DOCNO>NCT02486770</DOCNO>
	<brief_summary>This study evaluate safety profile pharmacokinetic behavior single administration Aerucin healthy adult three different dosage .</brief_summary>
	<brief_title>Study Single Doses IV Aerucin Healthy Adults</brief_title>
	<detailed_description>This Phase I trial conduct open label trial 15 healthy adult . All subject receive specific intravenous dose Aerucin . There three study group , specific dose Aerucin . Study Group 1 receive 2.0 mg/ kg Aerucin . Study Group 2 receive 8.0 mg/kg Aerucin . Study Group 3 receive 20 mg/kg Aerucin . The dose level Aerucin select study base animal study show protection animal model absence adverse effect toxicological study . Groups enrol sequentially .</detailed_description>
	<criteria>1 . Has complete write informed consent process 2 . Is male female 3 . Is age ≥18 year ≤50 year 4 . Agrees stay contact study site duration study , provide update contact information necessary , current plan move study area duration study 5 . Agrees avoid elective surgery duration study 6 . For female subject : agrees avoid pregnancy 14 day prior Study Day 0 duration study . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy period . Acceptable method avoid pregnancy include : sterile sexual partner ; sexual abstinence ( engage sexual intercourse ) ; hormonal contraceptive ( oral , injection , transdermal patch , implant ) ; vaginal ring ; intrauterine device ( IUD ) ; condom . 7 . Has general good health , confirm medical history physical examination 8 . Has body mass index ( BMI ) 18 30 ( weight/height ) 1 . Oral temperature ≥37.5°C 2 . Abnormal CBC laboratory value ( per local laboratory parameter ) blood collect screening ( &gt; 5 % ULN &gt; 5 % LLN ) 3 . Abnormally elevated laboratory value ( per local laboratory parameter ) blood collect screen ALT , AST , total bilirubin , alkaline phosphatase ( ALP ) , blood urea nitrogen ( BUN ) , creatinine ( Cr ) , ( &gt; 10 % ULN ) 4 . Abnormal urinalysis , opinion investigator , clinically significant 5 . Positive screening urine test illicit drug ( opiate , cocaine , amphetamine ) 6 . Has receive immunoglobulin product 120 day prior Study Day 0 7 . History evidence autoimmune disease 8 . History evidence past , present , future possible immunodeficiency state , include laboratory evidence HIV 1 infection . 9 . History evidence chronic hepatitis 10 . History evidence Pseudomonas infection 11 . Received systemic antibiotic 14 day prior Study Day 0 12 . Participation investigational study study period 13 . Received immunoglobulin blood product within 90 day prior Study Day 0 14 . Received investigational drug therapy investigational drug within 60 day prior Study Day 0 15 . Received immunosuppressive medication inhale topical immunosuppressant within 45 day prior Study Day 0 16 . Inability discontinue daily medication study : oral contraceptive , vitamin , nonprescription nutritional supplement , aspirin , antihistamine inhale corticosteroid , inhale beta agonist , inhale anticholinergic 17 . All female subject : currently pregnant lactating/nursing ; positive screening urine pregnancy test ; positive urine pregnancy test day study dose 18 . History evidence allergic disease reaction , opinion investigator , may compromise safety subject 19 . History evidence acute chronic disease , opinion investigator , may interfere evaluation safety immunogenicity drug compromise safety subject 20 . Medical , psychiatric , occupational , substance abuse problem , opinion investigator , make unlikely subject comply protocol 21 . Any reason discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>